Publications Plateforme NGS

  • 2017

Sharma S, Marchand V, Motorin Y, Lafontaine DLJ. Sci Rep. 2017 Sep 13;7(1):11490. Identification of sites of 2′-O-methylation vulnerability in human ribosomal RNAs by systematic mapping.

Marchand V, Ayadi L, El Hajj A, Blanloeil-Oillo F, Helm M, Motorin Y. Methods Mol Biol. 2017;1562:171-187. High-Throughput Mapping of 2′-O-Me Residues in RNA Using Next-Generation Sequencing (Illumina RiboMethSeq Protocol).

Marchand V, Pichot F, Thüring K, Ayadi L, Freund I, Dalpke A, Helm M, Motorin Y. Biomolecules. 2017 Feb 9;7(1). Next-Generation Sequencing-Based RiboMethSeq  Protocol for Analysis of tRNA 2′-O-Methylation.

  • 2016

Hauenschild R, Werner S, Tserovski L, Hildebrandt A, Motorin Y, Helm M. Biomolecules. 2016 Nov 10;6(4). CoverageAnalyzer (CAn): A Tool for Inspection of Modification Signatures in RNA Sequencing Profiles.

Schwartz S, Motorin Y. RNA Biol. 2016 Oct 28:1-14. Next-generation sequencing technologies for detection of modified nucleotides in RNAs.

Marchand V, Blanloeil-Oillo F, Helm M, Motorin Y. Nucleic Acids Res. 2016 Jun 14. Illumina-based RiboMethSeq approach for mapping of 2′-O-Me residues in RNA.

Tserovski L, Marchand V, Hauenschild R, Blanloeil-Oillo F, Helm M, Motorin Y. Methods. 2016 Feb 23. High-throughput sequencing for 1-methyladenosine (m1A) mapping in RNA.

  • 2015

Hauenschild R, Tserovski L, Schmid K, Thüring K, Winz ML, Sharma S, Entian KD, Wacheul L, Lafontaine DL, Anderson J, Alfonzo J, Hildebrandt A, Jäschke A, Motorin Y, Helm M. Nucleic Acids Res. 2015 Nov 16;43(20):9950-64. The reverse transcription signature of N-1-methyladenosine in RNA-Seq is sequence dependent.